Back to search results

Telemedicine for Older Adults with Cancer: The GAIN-S Trial

This study, called the GAIN-S Trial, is looking at how telemedicine (healthcare services provided remotely) can help older adults (age 65 and older) with cancer, especially those in underserved communities. Many cancer treatments are tested on younger people, so this study aims to see if a special assessment called a Geriatric Assessment (GA) can identify areas where older patients might need more support. You would either receive standard care or receive GA-based interventions (supportive care based on your assessment results) through telemedicine. Researchers will compare how well these approaches improve communication between doctors and patients, reduce costs, and potentially decrease treatment side effects. The study is currently recruiting 216 participants.

Study design
This is an interventional study where 216 participants will be randomly assigned to one of two groups: either receiving GA-based interventions through telemedicine or receiving standard care.
What's involved
You would complete a Geriatric Assessment at the beginning and at 3 months. If in the GAIN-S group, you would receive GA-based interventions using telemedicine over 6 months.
Compensation
Not stated in the trial record.
Follow-up
Researchers will measure outcomes at the start of treatment, 3 months after treatment initiation, and 6 months after treatment initiation.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06022965

Telemedicine for Improvement of Care for Older Adults With Cancer in the Underserved Community, The GAIN-S Trial

Recruiting
NAAges 65+InterventionalSupportive care
City of Hope Medical Center
~216 participants
Updated 2025-10-06 on ClinicalTrials.gov
What's tested:Best PracticeComprehensive Geriatric AssessmentElectronic Health Record ReviewQuestionnaire AdministrationSupportive CareTelemedicine

At a glance

Recruiting sites
3 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Rate of advance directive (AD) completion
Measured over At start of treatment and 3 months after treatment initiation
+2 more outcomes measured

Conditions

Hematopoietic and Lymphoid System Neoplasm
Malignant Solid Neoplasm

Explore related trials

Hematopoietic and Lymphatic System NeoplasmMalignant Solid Neoplasm

Where it's being run

3 sites across 1 states
California3

Study leadership

  • William Dale · PRINCIPAL_INVESTIGATOR · City of Hope Medical Center

Who to contact

William Dale
[email protected]
626-256-4673
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Documented informed consent of the participant.
Patient's physician must agree for patient participation.
Ability to read English, Spanish, or Chinese. Other languages will be acceptable with site principal investigator (PI) agreement if surveys are available, and language does not preclude completing study procedures.
Age: \>=65 years at the time of enrollment.
Diagnosis of stage I-IV cancer.
Scheduled to start a new therapy (chemotherapy, immunotherapy, or targeted therapy).

Exclusion

Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics).

What this trial measures

  • Rate of advance directive (AD) completionAt start of treatment and 3 months after treatment initiation

    Will be assessed using medical chart review. Chi-square test will be used to compare the proportions of AD completion between the two arms.

  • Number of documented conversations.At start of treatment and 3 months after treatment initiation

    Will be assessed using medical chart review. T-test will be used to compare the mean number of documented conversations between the two arms.

  • Direct inpatient costAt 3 and 6-months after treatment initiation

    Will log transformed and Z-score test will be used to compare the mean costs of the two arms. Chi-square test will be used to compare number of patients with short verse (vs.) long stay and Intensive Care Unit (ICU) admission between the two arms.